{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T13:36:08Z","timestamp":1790861768372,"version":"4.1.0"},"reference-count":11,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Neurology"],"published-print":{"date-parts":[[2000,7,25]]},"DOI":"10.1212\/wnl.55.2.236","type":"journal-article","created":{"date-parts":[[2012,5,13]],"date-time":"2012-05-13T13:47:37Z","timestamp":1336916857000},"page":"236-242","source":"Crossref","is-referenced-by-count":471,"title":["Levetiracetam for partial seizures"],"prefix":"10.1212","volume":"55","author":[{"given":"J.J.","family":"Cereghino","sequence":"first","affiliation":[{"name":"From Oregon Health Sciences University (Dr. Cereghino)Portland; Arkansas Epilepsy Program (Dr. Biton), Little Rock; Vanderbilt Medical Center (Dr. Abou-Khalil), Nashville, TN; University of Virginia Hospital (Dr. Dreifuss"},{"name":"\u2020), Charlottesville; UCB Pharma (L.J. Gauer), Smyrna, GA; and the Minnesota Comprehensive Epilepsy Program (Dr. Leppik), Minneapolis."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"Biton","sequence":"additional","affiliation":[{"name":"From Oregon Health Sciences University (Dr. Cereghino)Portland; Arkansas Epilepsy Program (Dr. Biton), Little Rock; Vanderbilt Medical Center (Dr. Abou-Khalil), Nashville, TN; University of Virginia Hospital (Dr. Dreifuss"},{"name":"\u2020), Charlottesville; UCB Pharma (L.J. Gauer), Smyrna, GA; and the Minnesota Comprehensive Epilepsy Program (Dr. Leppik), Minneapolis."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Abou-Khalil","sequence":"additional","affiliation":[{"name":"From Oregon Health Sciences University (Dr. Cereghino)Portland; Arkansas Epilepsy Program (Dr. Biton), Little Rock; Vanderbilt Medical Center (Dr. Abou-Khalil), Nashville, TN; University of Virginia Hospital (Dr. Dreifuss"},{"name":"\u2020), Charlottesville; UCB Pharma (L.J. Gauer), Smyrna, GA; and the Minnesota Comprehensive Epilepsy Program (Dr. Leppik), Minneapolis."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Dreifuss","sequence":"additional","affiliation":[{"name":"From Oregon Health Sciences University (Dr. Cereghino)Portland; Arkansas Epilepsy Program (Dr. Biton), Little Rock; Vanderbilt Medical Center (Dr. Abou-Khalil), Nashville, TN; University of Virginia Hospital (Dr. Dreifuss"},{"name":"\u2020), Charlottesville; UCB Pharma (L.J. Gauer), Smyrna, GA; and the Minnesota Comprehensive Epilepsy Program (Dr. Leppik), Minneapolis."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.J.","family":"Gauer","sequence":"additional","affiliation":[{"name":"From Oregon Health Sciences University (Dr. Cereghino)Portland; Arkansas Epilepsy Program (Dr. Biton), Little Rock; Vanderbilt Medical Center (Dr. Abou-Khalil), Nashville, TN; University of Virginia Hospital (Dr. Dreifuss"},{"name":"\u2020), Charlottesville; UCB Pharma (L.J. Gauer), Smyrna, GA; and the Minnesota Comprehensive Epilepsy Program (Dr. Leppik), Minneapolis."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.","family":"Leppik","sequence":"additional","affiliation":[{"name":"From Oregon Health Sciences University (Dr. Cereghino)Portland; Arkansas Epilepsy Program (Dr. Biton), Little Rock; Vanderbilt Medical Center (Dr. Abou-Khalil), Nashville, TN; University of Virginia Hospital (Dr. Dreifuss"},{"name":"\u2020), Charlottesville; UCB Pharma (L.J. Gauer), Smyrna, GA; and the Minnesota Comprehensive Epilepsy Program (Dr. Leppik), Minneapolis."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"the United States Levetiracetam Study Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/0014-2999(92)90855-X"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/0920-1211(95)00077-1"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0014-2999(98)00410-5"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/0014-2999(93)90768-D"},{"key":"e_1_3_2_6_2","first-page":"474","volume":"284","year":"1998","unstructured":"L\u00f6scher W, H\u00f6nack D, Rundfeldt C. Antiepileptogenic effects of the novel anticonvulsant levetiracetam (ucb L059) in the kindling model of temporal lobe epilepsy. J Pharmacol Exp Ther 1998;284:474\u2013479.","journal-title":"J Pharmacol Exp Ther"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0163-7258(99)00052-2"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0920-1211(96)00031-9"},{"key":"e_1_3_2_9_2","first-page":"250","volume":"27","year":"1999","unstructured":"Nicolas J-M, Collart P, Gerin B, et al. In vitro evaluation of potential drug interactions with levetiracetam, a new antiepileptic agent. Drug Metab Dispos 1999;27:250\u2013254.","journal-title":"Drug Metab Dispos"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1157.1998.tb05128.x"},{"key":"e_1_3_2_11_2","unstructured":"US Food and Drug Administration.\u201cCOSTART\u201d coding symbols for thesaurus of Adverse (sic) reaction terms. 5th ed. Rockville MD:DHHS 1995."},{"key":"e_1_3_2_12_2","doi-asserted-by":"crossref","unstructured":"Cramer JA Arrigo C Van Hammee G et al. Effect of levetiracetam on epilepsy-related quality of life. Epilepsia 2000 (in press).","DOI":"10.1111\/j.1528-1157.2000.tb00255.x"}],"container-title":["Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.neurology.org\/doi\/pdfdirect\/10.1212\/WNL.55.2.236","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,28]],"date-time":"2024-03-28T16:39:47Z","timestamp":1711643987000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.neurology.org\/doi\/10.1212\/WNL.55.2.236"}},"subtitle":["Results of a double-blind, randomized clinical trial"],"short-title":[],"issued":{"date-parts":[[2000,7,25]]},"references-count":11,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2000,7,25]]}},"alternative-id":["10.1212\/WNL.55.2.236"],"URL":"https:\/\/doi.org\/10.1212\/wnl.55.2.236","relation":{},"ISSN":["0028-3878","1526-632X"],"issn-type":[{"value":"0028-3878","type":"print"},{"value":"1526-632X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2000,7,25]]}}}